Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 7, 2004, Pages 739-747

  Langmead, L ^a   Feakins, R M ^a   Goldthorpe, S ^b   Holt, H ^b   Tsironi, E ^a   De Silva, A ^a   Jewell, D P ^b   Rampton, D S ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALOE VERA EXTRACT; C REACTIVE PROTEIN; HEMOGLOBIN; PLACEBO;

ACNE; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLATULENCE; FOOT PAIN; HISTOLOGY; HUMAN; MALE; OUTCOMES RESEARCH; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK; SIGMOIDOSCOPY; SORE THROAT; THROMBOCYTE COUNT; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADULT; AGED; ALOE; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; TREATMENT OUTCOME;

EID: 1942534231     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01902.x     Document Type: Article

References (37)

1. Hennessee O, Cook W. Aloe Myth, Magic and Medicine: Aloe Vera Across Time. Lawton, PA: Universal Graphics, 1989.
2. Syed TA, Ahmad SA, Holt AH, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: a placebo-controlled, double-blind study. Trop Med Int Health 1996; 1(4): 505-9.
3. Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93(5): 697-701.
4. Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: an internet survey. Can J Gastroenterol 1999; 13(4): 327-32.
5. Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res 1996; 40(5): 503-9.
6. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002; 8(3): 174-9.
7. Walmsley R, Ayres R, Pounder R, Allen R. A simple clinical colitis activity index. Gut 1998; 43: 29-32.
8. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106(2): 287-96.
9. Baron J, Connell A, Lennard-Jones A. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 189-92.
10. Saverymuttu S, Camilleri M, Rees H, et al. Indium-111 granulocyte staining in the assessment of disease extent and activity in inflammatory bowel disease. Gastroenterology 1986; 90: 112-8.
11. Ilnyckyj A, Shanahan F, Anton P, Cheang N, Burnstein C. Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997; 112: 1854-8.
12. Perneger TV. What's wrong with Bonferroni adjustments [see comments]. Br Med J 1998; 316(7139): 1236-8.
13. Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 1997: 2(1): 37-43.
14. Chen Q, Zhang H. Clinical study on 118 cases of ulcerative colitis treated by integration of traditional Chinese and Western medicine. J Tradit Chin Med 1999; 19(3): 163-5.
15. Wang B, Ren S, Feng W, Zhong Z, Qin C. Kui jie qing in the treatment of chronic non-specific ulcerative colitis. J Tradit Chin Med 1997; 17(1): 10-3.
16. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118(7): 540-9.
17. Marshall J. Aloe vera gel: what is the evidence? Pharm J 1990; 240: 360-2.
18. Davis RH, Parker WL, Samson RT, Murdoch DP. The isolation of an active inhibitory system from an extract of aloe vera. J Am Podiatr Med Assoc 1991; 81(5): 258-61.
19. Vazquez B, Avila G, Segura D, Escalante B. Antiinflammatory activity of extracts from Aloe vera gel. J Ethnopharmacol 1996; 55(1): 69-75.
20. Hutter JA, Salman M, Stavinoha WB, et al. Antiinflammatory C-glucosyl chromone from Aloe barbadensis. J Nat Prod 1996; 59(5): 541-3.
21. Strickland FM, Pelley RP, Kripke ML. Prevention of ultraviolet radiation-induced suppression of contact and delayed hypersensitivity by Aloe barbadensis gel extract. J Invest Dermatol 1994; 102(2): 197-204.
22. Byeon SW, Pelley RP, Ullrich SE, Waller TA, Bucana CD, Strickland FM. Aloe barbadensis extracts reduce the production of interleukin-10 after exposure to ultraviolet radiation. J Invest Dermatol 1998; 110(5): 811-7.
23. Lee CK, Han SS, Shin YK, et al. Prevention of ultraviolet radiation-induced suppression of contact hypersensitivity by Aloe vera gel components. Int J Immunopharmacol 1999; 21(5): 303-10.
24. Qiu Z, Jones K, Wylie M, Jia Q, Orndorff S. Modified Aloe barbadensis polysaccharide with immunoregulatory activity. Planta Med 2000; 66(2): 152-6.
25. t'Hart LA, Nibbering PH, van den Barselaar MT, van Dijk H, van den Berg AJ, Labadie RP. Effects of low molecular constituents from Aloe vera gel on oxidative metabolism and cytotoxic and bactericidal activities of human neutrophils. Int J Immunopharmacol 1990; 12(4): 427-34.
26. Lee KY, Weintraub ST, Yu BP. Isolation and identification of a phenolic antioxidant from Aloe barbadensis. Free Radic Biol Med 2000; 28(2): 261-5.
27. Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther in press.
28. Esteban A, Zapata JM, Casano L, Martin M, Sabater B. Peroxidase activity in Aloe barbadensis commercial gel: probable role in skin protection. Planta Med 2000; 66(8): 724-7.
29. Sabeh F, Wright T, Norton SJ. Isozymes of superoxide dismutase from Aloe vera. Enzyme Protein 1996; 49(4): 212-21.
30. t'Hart LA, van den Berg AJ, Kuis L, van Dijk H, Labadie RP. An anti-complementary polysaccharide with immunological adjuvant activity from the leaf parenchyma gel of Aloe vera. Planta Med 1989; 55(6): 509-12.
31. Ro JY, Lee BC, Kim JY, et al. Inhibitory mechanism of aloe single component (alprogen) on mediator release in guinea pig lung mast cells activated with specific antigen-antibody reactions. J Pharmacol Exp Ther 2000; 292(1): 114-21.
32. Karaca K, Sharma JM, Nordgren R. Nitric oxide production by chicken macrophages activated by Acemannan. a complex carbohydrate extracted from Aloe vera. Int J Immunopharmacol 1995; 17(3): 183-8.
33. Zhang L, Tizard IR. Activation of a mouse macrophage cell line by acemannan: the major carbohydrate fraction from Aloe vera gel. Immunopharmacology 1996; 35(2): 119-28.
34. Pugh N, Ross SA, El Sohly MA, Pasco DS. Characterization of Aloeride, a new high-molecular-weight polysaccharide from Aloe vera with potent immunostimulatory activity. J Agric Food Chem 2001; 49(2): 1030-4.
35. Stuart RW, Lefkowitz DL, Lincoln JA, Howard K, Gelderman MP, Lefkowitz SS. Upregulation of phagocytosis and candidicidal activity of macrophages exposed to the immunostimulant acemannan. Int J Immunopharmacol 1997; 19(2): 75-82.
36. Womble D, Helderman JH. Enhancement of allo-responsiveness of human lymphocytes by acemannan (Carrisyn). Int J Immunopharmacol 1988; 10(8): 967-74.
37. Newall C, Anderson L, Phillipson J. Herbal Medicines. A Guide for Healthcare Professionals. London: The Pharmaceutical Press, 1995.